An engineered 4-1BBL fusion protein with “activity on demand”

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

(2020) Leander Huyghe et al.   EMBO Molecular Medicine

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

(2020) Sun K. Ho et al.   MOLECULAR CANCER THERAPEUTICS

A universal reporter cell line for bioactivity evaluation of engineered cytokine products

(2020) Jacqueline Mock et al.   Scientific Reports

Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells

(2019) Cornelia Hutmacher et al.   Cancer Immunology Research

Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity

(2019) Dario Neri   Cancer Immunology Research

Tumor-localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343

(2019) Marlon J Hinner et al.   CLINICAL CANCER RESEARCH

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

(2019) Xinyue Qi et al.   Nature Communications

TOX is a critical regulator of tumour-specific T cell differentiation

(2019) Andrew C. Scott et al.   NATURE

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

(2019) Christina Claus et al.   Science Translational Medicine

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies

(2019) Kasper Mikkelsen et al.   Frontiers in Immunology

The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8 + T cell activity and synergizes with immune checkpoint inhibitors

(2019) Emanuele Puca et al.   INTERNATIONAL JOURNAL OF CANCER

Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation

(2019) Patrizia Murer et al.   New Biotechnology

Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice

(2019) Emanuele Puca et al.   JOURNAL OF CONTROLLED RELEASE

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway

(2018) Todd Bartkowiak et al.   CLINICAL CANCER RESEARCH

Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier

(2018) Aruna Bitra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses

(2018) Ashley V. Menk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structural principles of tumor necrosis factor superfamily signaling

(2018) Éva S. Vanamee et al.   Science Signaling

Structural principles of tumor necrosis factor superfamily signaling

(2018) Éva S. Vanamee et al.   Science Signaling

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy

(2018) Cornelia Hutmacher et al.   ADVANCED DRUG DELIVERY REVIEWS

Abstract 3029: FAP-mediated tumor accumulation of a T-cell agonistic FAP/4-1BB DARPin drug candidate analyzed by SPECT/CT and quantitative biodistribution

(2018) Christian Reichen et al.   CANCER RESEARCH

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding

(2018) Aruna Bitra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

(2018) Jong W. Yu et al.   PLoS One

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

(2018) Marta Compte et al.   Nature Communications

Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling

(2017) Aruna Bitra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis

(2017) Claus Madsen   Brain and Behavior

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

(2017) Anje Cauwels et al.   OncoImmunology

4-1BB agonism: adding the accelerator to cancer immunotherapy

(2016) Cariad Chester et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

(2016) D. H. Charych et al.   CLINICAL CANCER RESEARCH

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions

(2016) Franziska Bootz et al.   DRUG DISCOVERY TODAY

Rationale for anti-CD137 cancer immunotherapy

(2016) Amani Makkouk et al.   EUROPEAN JOURNAL OF CANCER

Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins

(2016) Dario Venetz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format

(2016) Sina Fellermeier et al.   OncoImmunology

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity

(2016) Sarah L. Pogue et al.   PLoS One

Trial Watch—Immunostimulation with cytokines in cancer therapy

(2015) Erika Vacchelli et al.   OncoImmunology

Side Effects of Cytokines Approved for Therapy

(2014) Brian A. Baldo   DRUG SAFETY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety

(2014) Patricia A. Young et al.   SEMINARS IN ONCOLOGY

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity

(2013) T Hemmerle et al.   BRITISH JOURNAL OF CANCER

A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity

(2013) S. D. Gillies   PROTEIN ENGINEERING DESIGN & SELECTION

Antibody–cytokine fusion proteins

(2012) Roland E. Kontermann   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel

(2012) N. Pasche et al.   CLINICAL CANCER RESEARCH

Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours

(2012) G. Spitaleri et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

(2011) T. K. Eigentler et al.   CLINICAL CANCER RESEARCH

Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors

(2011) Melissa G Lechner et al.   Immunotherapy

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

(2011) Katharina Frey et al.   Integrative Biology

A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer

(2011) Kathrin Schwager et al.   Head and Neck Optical Diagnostics Society

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

(2011) Volker Limmroth et al.   Therapeutic Advances in Neurological Disorders

Cytokines in Cancer Immunotherapy

(2011) Sylvia Lee et al.   Cancers

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

(2010) Manfred Johannsen et al.   EUROPEAN JOURNAL OF CANCER

Clinical Use of Interferon-γ

(2009) Catriona H.T. Miller et al.   Annals of the New York Academy of Sciences

Fc-Based Cytokines

(2009) Jalal A Jazayeri et al.   BIODRUGS

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

(2009) Kathrin Schwager et al.   ARTHRITIS RESEARCH & THERAPY

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo

(2008) Alessandra Villa et al.   INTERNATIONAL JOURNAL OF CANCER

New insights into form and function of fibronectin splice variants

(2008) ES White et al.   JOURNAL OF PATHOLOGY